Saama commissioned BioPharma Dive to survey pharma executives on the clinical research impact of COVID-19. More than a third of the companies represented in the survey were conducting clinical studies related to COVID-19, but the pandemic also had an impact on the nearly two thirds of companies that were studying other conditions.
Nearly two-thirds of respondents were likely to adopt an integrated data solution to improve clinical trial performance.
More than a quarter of respondents were eager to implement a remote monitoring solution.
Respondents who experienced clinical study delays related to COVID-19 have different opinions on when research will resume:
Not sure / Trials on hold
Sometime in 2021
2022 or later
Never, they have been canceled
Difficult / Time-
Nearly three-quarters of respondents were likely to adopt an integrated data solution to improve clinical trial performance.
More than half of respondents were likely to implement a technology platform to speed scientific data analysis.
More than a quarter of respondents expressed the need for an analytics solution that integrates clinical and biomarker data to enhance translational research.
While the pandemic has caused many problems for pharma, it has created opportunities for new treatments and vaccines and accelerated the much-needed digital transformation of the industry. Let Saama modernize your data collection and analytics efforts.Download Report
Eligibility details are for informational purposes only. Saama, in its sole discretion, will determine your eligibility based on the information you disclose as part of the intake process. If Saama determines that you are eligible to participate, you will be notified by separate email. Eligibility depends on certain criteria, such as the size of your company, the types of clinical trials you sponsor, and the number of patients in–and stages of–your current clinical trials.
By completing the request form, you represent that you have authority to proceed on behalf of your company. Should you agree to participate, you agree to reasonably cooperate with Saama in following the guidelines and procedures required for integrating, standardizing, and analyzing your data. Participation requires the use of our Smart Data Quality application, a technology-agnostic AI engine that sits on top of your current infrastructure. The application can be used immediately, and you’re only charged for the services you use based on a predetermined estimate.
Information you share with Saama during your participation may be anonymized and/or aggregated, and made available publicly in Saama marketing materials. This information may include: types of systems and processes involved, types of departments involved, and size and regional location of your company. Such information will never be directly associated with you, nor will you or your company be identifiable without express written permission.